Please Wait
Applying Filters...
menu
    • menu
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    USP reference standards; highly characterized specimens of drug substances, impurities, excipients, degradation products & more.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Guizhou Utide Biotechnology Co., Ltd. - Specialized GMP manufacturing for next-generation GLP-1 peptide APIs.

    Virtual Booth

    Contact Supplier

    Menu

    Tv003

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 31,944Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Takeda’s QDENGA Approved in Brazil for Use Regardless of Prior Dengue Exposure
    Takeda’s QDENGA Approved in Brazil for Use Regardless of Prior Dengue Exposure

    13 Mar 2023

    // PRESS RELEASE

    https://www.takeda.com/newsroom/newsreleases/2023/takedas-qdenga-approved-in-brazil

    PRESS RELEASE
    13 Mar 2023
    Share Share
    Takeda’s dengue vaccine QDENGA Approved for Use in EU
    Takeda’s dengue vaccine QDENGA Approved for Use in EU

    09 Dec 2022

    // PRESS RELEASE

    https://www.takeda.com/newsroom/newsreleases/2022/takedas-qdenga-dengue-tetravalent-vaccine-live-attenuated-approved-for-use-in-european-union/

    PRESS RELEASE
    09 Dec 2022
    Share Share
    CHMP offers +ve opinion for two high-profile drugs- latest batch recommendations
    CHMP offers +ve opinion for two high-profile drugs- latest batch recommendations

    15 Oct 2022

    // Paul Schloesser ENDPTS

    https://endpts.com/chmp-offers-positive-opinion-for-two-high-profile-drugs-as-part-of-latest-batch-of-recommendations/

    Paul Schloesser ENDPTS
    15 Oct 2022
    Share Share
    Takeda phase 3 TIDES trial of tetravalent dengue vaccine meets primary endpoint
    Takeda phase 3 TIDES trial of tetravalent dengue vaccine meets primary endpoint

    30 Jan 2019

    // PHARMABIZ

    http://www.pharmabiz.com/NewsDetails.aspx?aid=113788&sid=2

    PHARMABIZ
    30 Jan 2019
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.